The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma.
Rachna T. Shroff
No relevant relationships to disclose
Gauri R. Varadhachary
No relevant relationships to disclose
Christopher H. Crane
No relevant relationships to disclose
Jeffrey Edwin Lee
No relevant relationships to disclose
Jeffrey H. Lee
No relevant relationships to disclose
Linus Ho
No relevant relationships to disclose
Eric P. Tamm
No relevant relationships to disclose
Douglas B. Evans
No relevant relationships to disclose
James L. Abbruzzese
No relevant relationships to disclose
Robert A. Wolff
No relevant relationships to disclose